Halozyme Therapeutics Inc

24 de ago. de 2026, 23:36 UTC

Halozyme Therapeutics Inc shares are lower in after-market hours. Broader market concerns over geopolitical tensions are impacting investor confidence.

21 de ago. de 2026, 19:36 UTC

Halozyme Therapeutics Inc is trading higher, continuing its upward trend since Thursday's close. No specific news was identified to explain the movement.

20 de ago. de 2026, 20:06 UTC

Halozyme Therapeutics shares are lower amid concerns over recent insider selling by CEO Helen Torley, who sold $2.13 million in stock.

19 de ago. de 2026, 19:56 UTC

Halozyme Therapeutics shares are higher as investor confidence grows following the election of Dannielle Appelhans to its Board of Directors.

18 de ago. de 2026, 23:41 UTC

Halozyme shares are lower in after-market trading following the announcement of Dannielle Appelhans' election to the Board of Directors, effective August 2026.

17 de ago. de 2026, 23:02 UTC

Halozyme Therapeutics shares are higher in after-market hours, recovering from earlier session declines and remaining near the upper end of their one-month trading range.

14 de ago. de 2026, 20:06 UTC

Halozyme Therapeutics Inc shares are lower amid broader market concerns following a decline in U.S. retail sales, continuing a trend of volatility.

13 de ago. de 2026, 19:56 UTC

Halozyme Therapeutics Inc shares are lower during Thursday's session, having retraced from an earlier peak with no specific news to explain the decline.

12 de ago. de 2026, 19:16 UTC

Halozyme Therapeutics Inc shares are lower, pressured by a high Relative Strength Index indicating potential overbought conditions amid recent market sentiment.

11 de ago. de 2026, 20:02 UTC

Halozyme Therapeutics reported strong second-quarter earnings, raising full-year revenue guidance to $1.87 billion. Shares are trading roughly flat amid high trading volume.

10 de ago. de 2026, 22:36 UTC

Halozyme Therapeutics shares are higher in after-market trading, reaching a high above the 20-day moving average and near the upper end of its one-month range.

7 de ago. de 2026, 23:21 UTC

Halozyme Therapeutics reported strong Q2 earnings and raised guidance, yet shares are trading lower in after-market hours following notable weakness.

6 de ago. de 2026, 23:51 UTC

Halozyme Therapeutics shares advanced in after-market trading following record second-quarter results, with revenue rising to $481 million and guidance increased for the year.

5 de ago. de 2026, 22:16 UTC

Halozyme Therapeutics shares are lower in after-market trading, reflecting broader market pressures amid mixed sentiment from geopolitical developments and weak employment data.

4 de ago. de 2026, 19:22 UTC

Halozyme Therapeutics is higher today, driven by 39.1% revenue growth from its ENHANZE technology, which enhances market share and earnings performance.

3 de ago. de 2026, 19:46 UTC

Halozyme Therapeutics Inc. shares are lower today, despite earlier gains, amid a broader market rally following a significant drop in oil prices.

31 de jul. de 2026, 20:06 UTC

Shares of Halozyme Therapeutics are lower today, reflecting broader market trends amid rising U.S. Treasury yields and crude oil prices influencing inflation concerns.

30 de jul. de 2026, 19:58 UTC

Halozyme Therapeutics Inc shares are higher, reflecting a broader recovery in technology stocks amid improved market sentiment. The stock remains near its one-month range.

29 de jul. de 2026, 19:27 UTC

Halozyme shares are higher today, despite earlier pulling back. Recent commentary raises concerns about future performance and potential writedowns from acquisitions.

28 de jul. de 2026, 20:03 UTC

Halozyme Therapeutics Inc. is trading higher, benefiting from a broader upward trend in biotechnology stocks, despite a pullback earlier in the session.

27 de jul. de 2026, 19:46 UTC

Shares of Halozyme Therapeutics Inc. are lower today, continuing a decline since Friday. Broader market sentiment is affected by a drop in crude oil prices.

24 de jul. de 2026, 20:07 UTC

Halozyme Therapeutics is gaining traction as shares rise, supported by strong cash flow margins and revenue growth. The stock is currently priced at $80.60 per share.

22 de jul. de 2026, 19:35 UTC

Halozyme Therapeutics shares are lower today, despite an earlier peak gain. The decline follows a drop since Tuesday's close amid rising crude oil prices.